SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

Qing Zhang; Zhiwen Deng; Tudi Li; Kaitong Chen; Zhihuan Zeng

doi:10.3389/fcvm.2023.1280547

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

Front Cardiovasc Med. 2024 Jan 11:10:1280547. doi: 10.3389/fcvm.2023.1280547. eCollection 2023.

Authors

Qing Zhang¹, Zhiwen Deng¹, Tudi Li¹, Kaitong Chen¹, Zhihuan Zeng¹

Affiliation

¹ Department of Cardiovascular Diseases, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.

Abstract

Coronary heart disease is a narrowing or obstruction of the vascular cavity caused by atherosclerosis of the coronary arteries, which leads to myocardial ischemia and hypoxia. At present, percutaneous coronary intervention (PCI) is an effective treatment for coronary atherosclerotic heart disease. Restenosis is the main limiting factor of the long-term success of PCI, and it is also a difficult problem in the field of intervention. Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new oral glucose-lowering agent used in the treatment of diabetes in recent years. Recent studies have shown that SGLT2 inhibitors can effectively improve the prognosis of patients after PCI and reduce the occurrence of restenosis. This review provides an overview of the clinical studies and mechanisms of SGLT2 inhibitors in the prevention of restenosis, providing a new option for improving the clinical prognosis of patients after PCI.

Keywords: AMI—acute myocardial infarction; ASCVD-atherosclerotic cardiovascular disease; SGLT2 inhibitor; coronary heart disease; restenosis.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article.